跳转到内容

维司力农

维基百科,自由的百科全书
维司力农
臨床資料
AHFS/Drugs.com国际药品名称
给药途径口服给药
ATC碼
  • 未分配
法律規範狀態
法律規範
  • 处方药(-only)
识别信息
  • 6-[4-(3,4-Dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one
CAS号81840-15-5  checkY
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
化学信息
化学式C22H25N3O4
摩尔质量395.46 g·mol−1
3D模型(JSmol英语JSmol
  • COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC
  • InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26) ☒N
  • Key:ZVNYJIZDIRKMBF-UHFFFAOYSA-N ☒N

维司力农INN:vesnarinone)是一种强心剂[1]一种混合磷酸二酯酶3抑制剂和离子通道调节剂,具有适度的、剂量依赖性的正性肌力活性,但负性变时性活性极小。[2]有研究探索了维司力农用于治疗心力衰竭的安全性。[3][4]

参考资料

[编辑]
  1. ^ Cavusoglu E, Frishman WH, Klapholz M. Vesnarinone: a new inotropic agent for treating congestive heart failure. Journal of Cardiac Failure. June 1995, 1 (3): 249–257. PMID 9420657. doi:10.1016/1071-9164(95)90030-6. 
  2. ^ Feldman, Arthur M. Clinical characteristics of vesnarinone. Drug Safety. 2004,. 27 Suppl 1. ISSN 0114-5916. PMID 15293848. doi:10.2165/00002018-200427001-00002. 
  3. ^ Cohn, J. N.; Goldstein, S. O.; Greenberg, B. H.; Lorell, B. H.; Bourge, R. C.; Jaski, B. E.; Gottlieb, S. O.; McGrew, F.; DeMets, D. L.; White, B. G. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. The New England Journal of Medicine. 1998-12-17, 339 (25). ISSN 0028-4793. PMID 9854116. doi:10.1056/NEJM199812173392503. 
  4. ^ Feldman, A. M.; Bristow, M. R.; Parmley, W. W.; Carson, P. E.; Pepine, C. J.; Gilbert, E. M.; Strobeck, J. E.; Hendrix, G. H.; Powers, E. R.; Bain, R. P. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. The New England Journal of Medicine. 1993-07-15, 329 (3). ISSN 0028-4793. PMID 8515787. doi:10.1056/NEJM199307153290301. 

外部链接

[编辑]